Vivos Therapeutics, Inc. has signed an important deal with SOD Sciences to buy a small ownership stake.

Oct 19, 2026, 4:57 PM ETDealRead the original at SEC EDGAR

Neutral

VVOS received an 11% stake in SOD and half of its test rights, sharing future test income and costs equally. It paid with convertible preferred shares, and the filing gives no sales or profit estimate, so the deal does not change VVOS's outlook.

VVOS · Vivos Therapeutics, Inc.

AI read · Neutral

The AI's read

The test could bring income, but VVOS must share that income and its patent costs equally with SOD. The preferred shares can become common shares, which could reduce each current owner's slice. The filing gives no estimate of test sales or profit, so the possible gains do not clearly outweigh those costs.

Get alerts for VVOS

Follow Vivos Therapeutics, Inc. (VVOS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VVOS

Free on the App Store and Google Play, or on the web.